A Multicenter, Open-label, Extension Study to Evaluate the Long term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION) - SELECTED
Latest Information Update: 08 Jun 2021
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SELECTED
- Sponsors Biogen
- 01 Mar 2019 Results from case series from multiple clinical trials (205MS203, 205MS301, 205MS302 and 205MS303) published in the Respiratory Medicine
- 28 Sep 2016 This trial was completed in Hungary (End date: 30 Aug 2016).
- 24 Jun 2016 The trial was completed in Czech Republic.